Editas Medicine, Inc. (EDIT)

NASDAQ: EDIT · IEX Real-Time Price · USD
11.19
+2.33 (26.30%)
Feb 28, 2024, 1:34 PM EST - Market open
26.30%
Market Cap 727.71M
Revenue (ttm) 24.61M
Net Income (ttm) -195.08M
Shares Out 81.67M
EPS (ttm) -2.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,196,292
Open 10.24
Previous Close 8.86
Day's Range 9.58 - 11.58
52-Week Range 6.08 - 11.91
Beta 1.96
Analysts Buy
Price Target 14.10 (+26.29%)
Earnings Date Feb 28, 2024

About EDIT

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing g... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 3, 2016
Employees 226
Stock Exchange NASDAQ
Ticker Symbol EDIT
Full Company Profile

Financial Performance

In 2022, EDIT's revenue was $19.71 million, a decrease of -22.83% compared to the previous year's $25.54 million. Losses were -$220.43 million, 14.5% more than in 2021.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for EDIT stock is "Buy." The 12-month stock price forecast is $14.1, which is an increase of 26.29% from the latest price.

Price Target
$14.1
(26.29% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates

Company aligned with FDA that RUBY is a single Phase 1/2/3 trial On track to present additional clinical data from the RUBY trial and the EdiTHAL trial of reni-cel in mid-2024 and additional updates b...

6 hours ago - GlobeNewsWire

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events

CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on We...

7 days ago - GlobeNewsWire

Editas Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that management will participate in the following upc...

4 weeks ago - GlobeNewsWire

Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference

Anticipated 2024 milestones include: present reni-cel clinical data updates mid-year and year-end, initiate the RUBY clinical trial adolescent cohort, establish in vivo preclinical proof-of-concept fo...

7 weeks ago - GlobeNewsWire

Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the Company's President and CEO Gilmore O'Neill,...

2 months ago - GlobeNewsWire

2 gene-editing stocks reshaping hereditary disease treatments

Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal Drug Administration (FDA) approved a sickle...

Other symbols: NTLA
2 months ago - MarketBeat

Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9

Vertex Pharmaceuticals to obtain a non-exclusive license for Cas9 for CASGEVY™ (exagamglogene autotemcel) Agreement extends Editas Medicine's cash runway into 2026 CAMBRIDGE, Mass., Dec. 13, 2023 (GLO...

2 months ago - GlobeNewsWire

Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar

All RUBY patients with ≥5 months follow-up have achieved a normal hemoglobin level and a fetal hemoglobin level of >40%

2 months ago - GlobeNewsWire

Editas Medicine Announces Third Quarter 2023 Results and Business Updates

Company to provide a clinical update on the EDIT-301 RUBY trial for SCD and EdiTHAL trial for TDT in December at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored webi...

4 months ago - GlobeNewsWire

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar

Company to host a webinar to discuss EDIT-301 clinical data on Monday, December 11, at 1:00 p.m. ET Dr. Rabi Hanna from Cleveland Clinic Children's to present EDIT-301 clinical data at ASH on Monday, ...

4 months ago - GlobeNewsWire

Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events

CAMBRIDGE, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Fr...

4 months ago - GlobeNewsWire

Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease

CAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA) gran...

4 months ago - GlobeNewsWire

Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the grant of an inducement award to the Company's ne...

5 months ago - GlobeNewsWire

Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company's f...

5 months ago - GlobeNewsWire

Are Gene Therapy Stocks The Market's Next Big Winners?

It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASD...

5 months ago - MarketBeat

Editas Medicine Announces Upcoming Investor Events

CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that management will participate in the following upc...

6 months ago - GlobeNewsWire

Editas Medicine Announces Second Quarter 2023 Results and Business Updates

On track to dose 20 total patients in the EDIT-301 RUBY trial for SCD and provide a clinical update by year-end Commenced parallel patient dosing in the EDIT-301 EDITHAL trial for TDT and on track to ...

7 months ago - GlobeNewsWire

Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update

CAMBRIDGE, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on We...

7 months ago - GlobeNewsWire

Editas Medicine Reports Inducement Grant to New Chief Scientific Officer

CAMBRIDGE, Mass., July 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced the grant of an inducement award to the Company's new...

7 months ago - GlobeNewsWire

Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D.

CAMBRIDGE, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linda C. Burkly, Ph.D., as the Com...

7 months ago - GlobeNewsWire

Editas Medicine Announces Pricing of Offering of Common Stock

CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the pricing of an underwritten offering of 12,500,000...

9 months ago - GlobeNewsWire

Editas Medicine Announces Offering of Common Stock

CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of sha...

9 months ago - GlobeNewsWire

Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial

EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant

9 months ago - GlobeNewsWire

Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia

CAMBRIDGE, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a live webinar on Monday, June 12, ...

9 months ago - GlobeNewsWire